枸橼酸镁、氧化镁和硫酸镁补充对健康超重个体动脉僵硬度的效果:随机对照试验研究方案
本研究为随机双盲安慰剂对照试验,计划招募162名健康超重和轻度肥胖男女,进行24周干预,随机接受枸橼酸镁、氧化镁、硫酸镁(每种活性治疗每日镁总剂量450 mg)或安慰剂,主要结局为颈-股脉搏波传导速度(PWVc-f)测量的动脉僵硬度,次要结局为诊室血压和肠道微生物群,旨在探讨不同镁制剂对心血管风险标志物的长期影响。
要点
- 研究比较枸橼酸镁、氧化镁、硫酸镁与安慰剂对动脉僵硬度的影响,每日镁总剂量均为450 mg。
- 主要结局为颈-股脉搏波传导速度(PWVc-f),次要结局包括诊室血压和肠道微生物群。
- 计划招募162名健康超重和轻度肥胖男女,干预24周,测量在基线及第2、12、24周进行。
核心结论
- 本研究预期为不同镁制剂(有机和无机)对动脉僵硬度和血压等心血管风险标志物及人类肠道微生物群的影响提供证据,可能有助于轻度肥胖但其他方面健康个体的心血管疾病一级预防。
研究设计与样本
- 随机、双盲、安慰剂对照试验,计划招募162名健康超重和轻度肥胖男女,干预24周,随机分配至枸橼酸镁、氧化镁、硫酸镁(每种活性治疗每日镁总剂量450 mg)或安慰剂组。
主要发现
- 主要结局为颈-股脉搏波传导速度(PWVc-f)测量的动脉僵硬度,次要结局为诊室血压(连续血压监测设备测量)和粪便样本中的肠道微生物群,测量在基线及第2、12、24周进行。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Arterial stiffness is closely related to the process of atherosclerosis, an independent cardiovascular risk factor, and predictive of future cardiovascular events and mortality. Recently, we showed that magnesium citrate supplementation results in a clinically relevant improvement of arterial stiffness. It remained unclear whether the observed effect was due to magnesium or citrate, and whether other magnesium compounds may have similar effects. Therefore, we aim to study the long-term effects of magnesium citrate, magnesium oxide and magnesium sulfate on arterial stiffness. In addition, we aim to investigate possible underlying mechanisms, including changes in blood pressure and changes in gut microbiota diversity. METHODS: In this randomized, double-blind, placebo-controlled trial, a total of 162 healthy overweight and slightly obese men and women will be recruited. During a 24-week intervention, individuals will be randomized to receive: magnesium citrate; magnesium oxide; magnesium sulfate (total daily dose of magnesium for each active treatment 450 mg); or placebo. The primary outcome of the study is arterial stiffness measured by the carotid-femoral pulse wave velocity (PWVc-f), which is the gold standard for quantifying arterial stiffness. Secondary outcomes are office blood pressure, measured by a continuous blood pressure monitoring device, and gut microbiota, measured in fecal samples. Measurements will be performed at baseline and at weeks 2, 12 and 24. DISCUSSION: The present study is expected to provide evidence for the effects of different available magnesium formulations (organic and inorganic) on well-established cardiovascular risk markers, including arterial stiffness and blood pressure, as well as on the human gut microbiota. As such, the study may contribute to the primary prevention of cardiovascular disease in slightly obese, but otherwise healthy, individuals. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03632590 . Retrospectively registered on 15 August 2018.
引用
- Schutten JC, Joris PJ, Mensink RP, et al. Effects of magnesium citrate, magnesium oxide and magnesium sulfate supplementation on arterial stiffness in healthy overweight individuals: a study protocol for a randomized controlled trial. Trials. 2019. PMID: 31138315. doi:10.1186/s13063-019-3414-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。